About
ImageneBio, Inc is a clinical-stage biotechnology company developing investigational therapeutics, including an anti-OX40 monoclonal antibody called Olevaprubart, for immunological, autoimmune, and inflammatory diseases.
Explore ImageneBio, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.